Inclusion Criteria:

1. Histologically confirmed relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's Disease (WHO criteria), for which standard curative or palliative measures do not exist or are no longer effective.
2. Must have received first line chemotherapy. No upper limit to number of prior therapies
3. Evaluable Disease
4. Age >18 years.
5. ECOG performance status <2
6. Life expectancy of greater than 3 months.
7. Patients must have adequate organ and marrow function
8. Adequate Contraception
9. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Prior Therapy

   • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
   • Patient is on any systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day prednisone during the 30 days prior to the start of the study drugs.
   • No monoclonal antibody within 3 months without evidence of progression
   • Prior history of receiving etoposide is not a contraindication
2. Patients may not be receiving any other investigational agents.
3. Patients with known central nervous system metastases, including lymphomatous meningitis
4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat, niacinamide or etoposide
5. Uncontrolled intercurrent illness
6. Pregnant women
7. Nursing women
8. Patient with a history of a prior malignancy
9. Patient is known to be Human Immunodeficiency Virus (HIV)-positive, if CD4 count is less than 200
10. Active Hepatitis A, Hepatitis B, or Hepatitis C infection
11. Patient has a history of surgery that would interfere with the administration or absorption of the oral study drugs
12. Prior or concurrent therapy with any Histone Deacetylase Inhibitor, including valproic acid